Trends in US sunscreen formulations: Impact of increasing spray usage
To the Editor: Sunscreen is an important component of sun protection. Almost all dermatologists believe that sunscreen is safe, effective, and can reduce the risk of skin cancer. 1 In the United States, many different sunscreen formulations exist, including balms, sprays, lotions, sticks, creams, foams, gels, and oils. Sunscreen sales have increased steadily over the past 5 years, with the 2 most popular formulations being lotions and clear aerosol sprays. 2 While lotion sunscreens have historically dominated the market, aerosol clear spray formulations are becoming increasingly popular and more frequently used. The purpose of this study was to examine sales of commonly used sunscreen formulations over the previous 5 years to elucidate trends in patient sunscreen preferences.
A cross-sectional study was performed using US sunscreen sales data from 2011 to 2016 including the absolute number of units sold for each sunscreen formulation available for each studied year. 2 Calculations were made to determine the market shares of the most popular sunscreen formulations and compound annual growth rates (CAGRs) were computed where appropriate. This study was exempt from institutional review board approval.
From 2011 to 2016, the total number of sunscreen units sold in the United States increased from 153,870,186 to 161,882,779 (CAGR ¼ 1.0%). Lotion and spray formulations dominated the market, making up [80% of the units purchased (combined) during every year of the interval studied. The percentage of lotion formulations decreased from 46.3% to 43.1% (CAGR ¼ À0.42%) between 2011 and 2016. Conversely, the percentage of spray sunscreens increased from 35.1% to 38.0% (CAGR ¼ 2.6%) over the same interval (Fig 1) .
Overall, sunscreen purchases appear to be increasing at a rate only slightly greater than that of the US population (CAGR ¼ 0.8%). Patient preferences have shifted away from lotions toward spray sunscreens, as consumers appear to enjoy this formulation for its quick and easy application. However, effective application may be affected by many factors, including wind, distance from the skin, and angle of application or duration of the spraying. 3 Dermatologists agree that the best form of sunscreen is one that is actually used regularly. 1 Spray sunscreens have proven to be equally efficacious to lotions. 4 Despite their increasing popularity and proven efficacy when applied correctly, the use of spray sunscreens has not been uniformly accepted. In a recent survey, 99% of 540 dermatologists recommended sunscreens to their patients, but only 69% recommended spray formulations. 1 Both the US Food and Drug Administration and the American Academy of Dermatology have recommendations for the application of lotion sunscreen formulations to adequately cover exposed body parts. 5 However, no such guidelines exist for spray formulations. The lack of application guidelines and consumer safety concerns regarding aerosol sunscreens 6 may explain the hesitancy of some dermatologists to recommend sprays and may lead to inadequate application by patients.
If current trends continue, sprays will soon overtake lotions as the primary sunscreen formulation. Given this fact, dermatologists and manufacturers need to work together to establish guidelines for optimal application and usage of spray sunscreens to achieve the maximal skin cancer prevention benefit. Several trials have shown the benefits of topical nitrates, 1,2 but there is a lack of evidence for the efficacy of other topical agents. The objective of the study was to compare the vasodilator efficacy of topical 10% nifedipine versus 5% sildenafil in subjects with secondary RP associated with connective tissue disease. A prospective study was performed including 10 patients with secondary RP. We excluded tobacco smokers, patients with primary RP, hypotension, hypertension, myocardial infarction, stroke, or arrhythmia. Patients who were being treated with a vasodilator were required to discontinue use for at least 24 hours before randomization. Patients' hands were randomized to treatment with 5 g of 10% nifedipine cream on one hand and 5 g of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve topical absorption, leaving the thumbs out of the gloves without any cream (control group). All patients underwent a high-frequency color Doppler ultrasound examination before and 1 hour after topical application. The temperature of the waiting and examination rooms was set at 668F. The radiologist was blinded to the treatment groups, and subsequent analysis was blinded to ultrasound results. The primary outcome was the improvement of blood flow in digital arteries using the peak systolic velocity. The secondary outcome was the increase of vessel diameter. For each hand, we obtained the differences of digital artery blood flows and diameters at baseline and after 60 minutes. Therefore, mean differences \0 indicated that the study cream was effective. Our findings are summarized in Tables I and II. Topical sildenafil significantly increased blood flow by 9.2 mm/sec (P \ .0083), while a trend toward improvement was observed for diameter (P ¼ .0695). After topical nifedipine, there was no significant improvement in blood flow or diameter. Five of 10 hands using nifedipine experienced sensation of heat and 6 of 10 hands with sildenafil developed a tingling sensation. No serious adverse effects were detected. Secondary RP is often refractory to standard therapies and is a therapeutic challenge. Current evidence supports the use of an oral calcium-channel blocker (eg, nifedipine) or synthetic prostacyclin analogue (iloprost), but substantial evidence is lacking for other agents. 3 There is limited evidence regarding the effectiveness of topical vasodilators for the management of RP. Only 1 study investigated the vasodilator effect of nifedipine gel on patients with RP, demonstrating an improvement of capillary circulation. 4 No previous study has evaluated the efficacy of topical sildenafil. We found that 5% sildenafil cream improved the digital arterial blood flow in patients with secondary RP, suggesting local vasodilatation. A limitation was the small sample size. Although there was a brief washout period, the cohort ideally would have 
